みらかホールディングス株式会社

これまで50年以上の間、1つの検体、1つの検査の向こう側に存在する『いのち』を常に意識し続け、臨床検査の質の向上、より良い製品やサービスの提供に取り組んでまいりました。

昨今、医療をとりまく環境は急速に変化しております。高齢化社会の進展に伴い増加する医療費の削減は、喫緊の課題となっております。一方、医療の可能性は、先進的な創薬・治療の研究・開発にとどまらず、人口知能（AI）やビックデータの活用といった幅広い領域にまで飛躍的に広がっております。医療の変化に伴い、臨床検査の担う役割も、診断から未病予防、健康管理、さらには生活の質（QOL）の向上にまで、ますます大きくなりつつあります。

このような環境のなか、みらかグループは2017年を第二の創業として、グループが一体となって新たなスタートを切りました。ロゴマークを刷新するとともに、新たにブランドメッセージを作成し、「みらからしさ」を社内外へ発信していきます。

これから、みらかグループは臨床検査、検査試薬を中心とした「ヘルスケアグループ」として新たなステージへ進みます。
グループ各社の連携とグループシナジー効果を生かした、より高い成長を目指してまいります。既存事業では、各事業での専門性とグループ全体の総合力を生かした製品開発やサービス向上に注力しつつ、人々の健康管理や豊かな社会づくりにつながる新たな事業も模索してまいります。

人と医療のまんなかで、― みらかグループは人々と医療の架け橋となり、健康な未来を実現してまいります。

The Miraca Group primarily focuses its business activity on clinical laboratory testing and in vitro diagnostics. For more than 50 years, we have endeavored to improve the quality of clinical testing and provide ever more superior products and services, while always keeping foremost in mind the fact that, behind every sample we treat or test we perform, is a precious human life.

The healthcare environment has undergone rapid changes in recent years. The need to reduce medical costs, which continue to rise with the aging of society, has become a critical issue. On the other hand, the potential of healthcare has expanded dramatically beyond the scope of research and development of advanced drugs and treatments, to a wide range of fields such as artificial intelligence (AI) and big data. As medical technology advances and the healthcare environment evolves, the role of clinical testing continues to grow, extending past medical diagnosis to encompass presymptomatic disease prevention, health management, and even quality of life (QOL) improvement.

With these circumstances in mind, the Miraca Group redefined itself as a single unified group in 2017, marking a new start for us all. In addition to redesigning our corporate logo, we have created a new brand message that universally conveys the unique characteristics and values of the Miraca Group.

As the Miraca Group enters a new stage, we will make sustained and concerted efforts as a healthcare group to build upon our core segments of clinical laboratory testing and in vitro diagnostics, while expanding our areas of business. By fostering closer cooperation between each company, we will strive to leverage group synergy and achieve even greater growth. In our existing businesses, we will continue to draw upon our expertise in each field and our comprehensive strength as a group to develop high-quality products and enhance our services. Furthermore, we will embrace the challenge of developing new businesses that promote health management and contribute to the creation of a healthy and prosperous society.

Moving forward, the Miraca Group reaffirms its commitment to serve as “the bridge between people and healthcare”, in pursuit of our mission to realize a healthier future for all.